Wu C-Y, Chen D-Y, Shen J-L, Ho HJ, Chen C-C, Kuo KN, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014;16:1–12.
Love T, Solomon DH. The relationship between cancer and rheumatoid arthritis: still a large research agenda [Editorial]. Arthritis Res Ther. 2008;10:109.
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
Pundole X, Suarez-Almazor ME. Cancer and Rheumatoid Arthritis. Rheum Dis Clin N Am. 2020;46:445–62.
Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26:794–804.
Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, Van Der Heijde D, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1113–36.
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605–21.
Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford). 2012;51:7–23.
Baecklund E, Smedby KE, Sutton L-A, Askling J, Rosenquist R. Lymphoma development in patients with autoimmune and inflammatory disorders–what are the driving forces? Semin Cancer Biol. 2014;24:61–70.
Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56:2563–9.
Mastroeni P, Villarreal-Ramos B, Hormaeche C. Effect of late administration of anti-TNα antibodies on a Salmonella infection in the mouse model. Microb Pathog. 1993;14:473–80.
Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;13:135–41.
Cho S-K, Lee J, Han M, Bae S-C, Sung Y-K. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs. Arthritis Res Ther. 2017;19:277.
Lan J-L, Tseng C-H, Chen J-H, Cheng C-F, Liang W-M, Tsay GJ. Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor. Medicine (Baltimore). 2017;96:e6055.
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
Buchbinder R, Van Doornum S, Staples M, Lassere M, March L. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study. BMC Musculoskelet Disord. 2015;16:309.
Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308:898–908.
Strangfeld A, Hierse F, Rau R, Burmester G-R, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:R5.
Raaschou P, Simard JF, Hagelberg CA, Askling J, ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016;352:i262.
Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–8.
Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76:386–91.
Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2017;76:497–503.
Cheol Seong S, Kim Y-Y, Khang Y-H, Heon Park J, Kang H-J, Lee H, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46:799–800.
Song YJ. The South Korean health care system. Jpn Med Assoc J. 2009;52:206–9.
Cho S-K, Sung Y-K, Choi C-B, Kwon J-M, Lee E-K, Bae S-C. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatol Int. 2013;33:2985–92.
Kim Y-H, Cho K-H, Kim KH, Ryu EJ, Han KD, Kim J-S. Predicting hypertension among Korean cancer survivors: a nationwide population-based study. Eur J Cancer Care (Engl). 2018;27:e12803.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid Arthritis Classification Criteria. Arthritis Rheum. 2010;2010(62):2569–81.
Seo HJ, Oh I-H, Yoon S-J. A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2012;13:6163–8.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410–5.
Cho J, Choi YJ, Suh M, Sohn J, Kim H, Cho SK, et al. Air pollution as a risk factor for depressive episode in patients with cardiovascular disease, diabetes mellitus, or asthma. J Affect Disord. 2014;157:45–51.
Kim J, Rhee CK, Yoo KH, Kim YS, Lee SW, Park YB, et al. The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data. Int J Chron Obstruct Pulmon Dis. 2013;8:561–8.
Lee JW, Kim HK, Woo YS, Jahng J, Jin YR, Park JH, et al. Optimal operational definition of patient with peptic ulcer bleeding for big data analysis using combination of clinical characteristics in a secondary general hospital. Korean J Gastroenterol. 2016;68:77–86 [Article in Korean].
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625–39.
Park I-S, Kim Y-M, Choi Y-H, Kim S-S, Kim E-J, Won S-Y, et al. Development of advanced TB case classification model using NHI claims data. J Digit Converg. 2013;11:289–99 [Article in Korean].
Jung SM, Kwok S-K, Ju JH, Park Y-B, Park S-H. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data. Korean J Intern Med. 2019;34:669–77.
Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74:2137–43.
Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm. 2017;23:809–14.
Maini R, Clair E-W, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932–9.
Guillem EB, Sampsel JW. Immune-promoted tumor cell invasion and metastasis. New considerations in cancer therapy. Adv Exp Med Biol. 2003;532:153–73.
Egberts J-H, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, et al. Anti–tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008;68:1443–50.
Guillem EB, Sampsel JW. Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy. Adv Exp Med Biol. 2006;587:341–74.
Hamaguchi T, Wakabayashi H, Matsumine A, Sudo A, Uchida A. TNF inhibitor suppresses bone metastasis in a breast cancer cell line. Biochem Biophys Res Commun. 2011;407:525–30.
Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 1997;40:1580–6.
Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller G, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996;32A:1753–7.
Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.
Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000;88:497–502.
Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45.
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res. 2015;21:756–62.
Charvat H, Sasazuki S, Inoue M, Iwasaki M, Sawada N, Shimazu T, et al. Impact of five modifiable lifestyle habits on the probability of cancer occurrence in a Japanese population-based cohort: results from the JPHC study. Prev Med. 2013;57:685–9.
Abásolo L, Júdez E, Descalzo MA, González-Álvaro I, Jover JA, Carmona L, et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2008;37:388–97.
Tseng H-W, Lu L-Y, Lam H-C, Tsai K-W, Huang W-C, Shiue Y-L. The influence of disease-modifying anti-rheumatic drugs and corticosteroids on the association between rheumatoid arthritis and skin cancer: a nationwide retrospective case-control study in Taiwan. Clin Exp Rheumatol. 2018;36:471–8.